MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by ImmunoGen, Inc.

< Previous 1 2 Next >
ImmunoGen Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of ImmunoGen's ADC Technology in the Development of Novel Targeted Conditioning Agents
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Appoints Michael Vasconcelles, MD, as Executive Vice President, Research, Development, and Medical Affairs
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Susan Altschuller on FMLA Leave; Interim CFO Appointed
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Webcast of Presentation and Q&A at the 41st Annual J.P. Morgan Healthcare Conference
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Clinical Collaboration with Gilead to Evaluate Pivekimab Sunirine in Combination with Magrolimab in Relapsed/Refractory Acute Myeloid Leukemia
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Appoints Daniel Char as Senior Vice President and Chief Legal Officer
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Reports Recent Progress and Third Quarter 2022 Financial Results
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Departure of Chief Commercial Officer
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Presents Retrospective Analysis of Extended Treatment Benefit from Multiple Trials of Mirvetuximab Soravtansine in Ovarian Cancer at ESGO
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Presents Comprehensive Updates for Mirvetuximab Soravtansine Combination Data in Ovarian Cancer at IGCS
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Guggenheim Nantucket Therapeutics Conference
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Presents Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Provides Update on Pivotal CADENZA Study of Pivekimab Sunirine in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Reports Recent Progress and Second Quarter 2022 Financial Results
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ASCO
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming H.C. Wainwright Global Investment Conference
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Reports Recent Progress and First Quarter 2022 Financial Results
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
Tickers IMGN
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
TOP
Email a Story